blinatumomab
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
FDA Approves Amgen's Blincyto as Consolidation Treatment in Certain Pediatric, Adult ALL Patients
Adult and pediatric patients with CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL will be eligible for the treatment.
Amgen's Lumakras Reports Double-Digit Sales Growth in Q1
The KRAS inhibitor recorded $82 million in sales in Q1 2024, up 11 percent compared to $74 million during the year-ago period.
The bispecific immunotherapy Blincyto saw the largest increase in Q4 2023 revenue, a 47 percent jump from the same period in 2022.
Blincyto sales continue to grow following positive data last year in acute lymphoblastic leukemia and an update to NCCN guidelines for pediatric patients.